Research & Development
Pathology & AI
Laboratory Information Systems (LIS): Page 2
Grail, AstraZeneca to collaborate on companion diagnostic tests
The firms will focus first on developing CDx tests using Grail's methylation platform to identify and recruit patients with high-risk, early-stage cancer for AstraZeneca's clinical studies.
June 1, 2022
Agilent secures CE-IVD Mark for cervical cancer test
PD-L1 is an antibody expressed by cervical cancer tumors and is a key biomarker for predicting response to anti-PD-L1 therapies like Keytruda, according to Agilent. The company's PD-L1 IHC 22C3 pharmDx companion diagnostic identifies cervical cancer patients with a PD-L1 combined positive score of one or more, which indicates that they could benefit from treatment with Keytruda, the company said.
May 10, 2022
Pandemic silver lining: COVID drives digital pathology adoption
During the presentation, Dr. Liron Pantanowitz, a professor of pathology and the director of anatomic pathology at the University of Michigan, offered a glimpse into the future of pathology -- both at work and in teaching -- once the pandemic has passed.
March 21, 2022
Foundation Medicine nabs FDA clearance for NSLC diagnostic
The test received FDA clearance in February for identifying patients with microsatellite instability-high solid tumors who may benefit from pembrolizumab (Keytruda) treatment. FoundationOne CDx can now also be used as a companion diagnostic to identify patients with NSCLC whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) alterations.
March 17, 2022
Guardant wins new clearances in Japan for liquid biopsy test
The MHLW has cleared Guardant360 CDx for mutation profiling in patients with advanced solid tumors. In addition, it approved Guardant360 CDx as a companion diagnostic for identifying patients with microsatellite instability-high solid tumors who may benefit from pembrolizumab (Keytruda). What's more, Guardant360 CDx has also been approved for patients with MSI-High advanced colorectal cancer who may benefit from nivolumab (Opdivo).
March 14, 2022
Labs need to improve functionality, security of LIS
Achieving operational efficiencies throughout the lab is integral for diagnostic providers, requiring an LIS infrastructure that is functional, reliable, interoperable, and highly secure. As the U.S. moves toward an endemic approach to infectious disease, which will continue to drive testing, these survey results highlight significant shortcomings, the company said.
February 27, 2022
Genetic causes identified for three rare diseases
Researchers in study validate test to identify newborns with homocystinuria, a rare inherited disease
SARS-CoV-2 infection weakens immune-cell response to vaccination, study suggests
Duke University researchers discover biomarkers may identify early pancreatic cancer risk
Werfen completes $2B acquisition of Immucor, expands presence in specialized diagnostics
Chembio CEO urges stockholders to tender remaining shares as deadline is extended for acquisition
FDA clears Foundation Medicine's companion diagnostic
Characterizing these tumors helps clinicians identify patients who could benefit from immunotherapy such as Keytruda, a humanized antibody used in cancer immunotherapy, the company said. MSI-H status is a defining feature of colorectal, endometrial, and gastrointestinal cancers.
February 22, 2022
Invitae launches 2 IVD cancer tests in Europe
Both tests offer comprehensive genomic profiling and companion diagnostic use for solid tumor neoplasms, including non-small cell lung cancer, in tissue biopsy and where tissue is a limiting factor.
February 15, 2022
Digital pathology recovers from COVID setback
The digital pathology market, which consists of hardware, software, and related services for clinical applications, has largely benefitted from the COVID-19 pandemic, allowing pathologist to read, evaluate, and collaborate remotely, improving efficiency and productivity.
February 2, 2022
CliniSys acquires Horizon Lab, combines with Sunquest
Together, the companies have more than 1,300 employees in 12 countries. The companies said that the newly formed group will enable improved public health outcomes through innovation in diagnostics and laboratory informatics technology.
January 17, 2022
Pillar's NGS lab receives certification, state permit
The Natick, MA-based lab also received the state permit. All of this means the lab can support preclinical studies and clinical trials, with the longer-term potential to provide companion diagnostics for the company's pharmaceutical partners.
January 9, 2022
ASH 2021: What technologies will disrupt hematology diagnostics?
Changing how clinicians approach medicine
December 10, 2021
Page 2 of 16